Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Core Insights - Vir Biotechnology (NASDAQ: VIR) is developing treatments for hepatitis B (HB) and hepatitis delta (HD) and is expected to report data in the oncology space that may positively impact its stock performance [1] Company Developments - The company has been focusing on trading around significant events such as trial results and NDA/BLA approvals, indicating a strategic approach to market movements [1]